<?xml version="1.0" encoding="UTF-8"?>
<p id="Par50">Currently, HCQ is used in the treatment of COVID-19 in most countries and for prophylaxis in some. However, considering the lack of evidence supporting its prophylactic use and the risk of short supplies for patients who need this drug, prophylactic treatment should not be recommended at this stage. Monti et al. reported that 51 out of 80 (64%) COVID-19 patients with SLE were taking HCQ/chloroquine (CQ) before infection with SARS-CoV-2 [
 <xref ref-type="bibr" rid="CR34">34</xref>]. Moreover, the frequency of hospitalization did not differ with regard to HCQ/CQ use [
 <xref ref-type="bibr" rid="CR34">34</xref>].
</p>
